Response to the letter to the Editor concerning our article "High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany"
- PMID: 31701271
- DOI: 10.1007/s00520-019-05126-z
Response to the letter to the Editor concerning our article "High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany"
References
-
- Cransac A, Aho S, Boulin M (2019) Comments on: high adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany. Support Care Cancer:1–2. https://doi.org/10.1007/s00520-019-04886-y
-
- Feiten S, Chakupurakal G, Feustel HP, Maasberg M, Otremba B, Ehscheidt P, Hensel M, Hansen R, Weide R (2019) High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany. Support Care Cancer 27:4265–4271. https://doi.org/10.1007/s00520-019-04721-4 - DOI - PubMed
-
- Foulon V, Schoffski P, Wolter P (2011) Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg 66(2):85–96. https://doi.org/10.2143/ACB.66.2.2062525 - DOI - PubMed
-
- Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS (2006) Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 44(5):471–477. https://doi.org/10.1097/01.mlr.0000207817.32496.cb - DOI - PubMed
-
- Vermeire E, Hearnshaw H, Van Royen P, Denekens J (2001) Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 26(5):331–342 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical